louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT05420428: Applying High Resolution Impedance Manometry for Perioperative Swallowing Changes in Older Patients Receiving Endotracheal Intubation or Supraglottic Airway Devices During Orthopedic Surgery
Official title: Applying High Resolution Impedance Manometry for Perioperative Swallowing Changes in Older Patients Receiving Endotracheal Intubation or Supraglottic Airway Devices During Orthopedic Surgery: a Pilot Randomized Controlled Trial
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Hypopharyngeal Mean Pressure
Lead sponsor: National Taiwan University Hospital
Sponsor class: OTHER
First posted: 2022-06-15
Enrollment: 32
Sex: ALL
Minimum age (years): 60
Maximum age (years): 80
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Intervention model description: controll group: tracheal intubation; intervention group: supraglottic airway device
Primary purpose: PREVENTION

Brief summary: We aimed to investigate whether patients with tracheal intubation has high hypopharyngeal pressure than patients with supraglottic airway does by using high resolution impedance manometry. We expected that the patients with endotracheal intubation have higher hypopharyngeal pressure than the patients with supraglottic airway devices.

Detailed description: Background: More and more older patients required to receive orthopedic surgery recently. The intubation or supraglottic airway device are required to maintain airway during general anesthesia. Previous studies only reported the subjective swallowing discomfort feeling, however, the objective data was limited. The high-resolution impedance manometry could detect the swallowing muscle power changes with multiple pressure sensors and impedance channels.

Objectives: we aimed to investigate whether patients with tracheal intubation has high hypopharyngeal pressure than patients with supraglottic airway does Patients and methods: The patients receive orthopedic surgery with older than 60 years old. They received high resolution impedance manometry examination at preoperative day, in the post-anesthetic care unit, postoperative day 3 to 7 (pick a day) along with subjective questionnaires. We also followed the IDDSI guideline to test different viscosity of the patients' tolerance for food.

Expected result: The patients with endotracheal intubation have higher hypopharyngeal pressure than the patients with supraglottic airway devices.

Eligibility criteria: Inclusion Criteria:

* The patients receive orthopedic surgery with older than 60 years old including 60 years old.

Exclusion Criteria:

* The patients had severe major organ dysfunction

Primary outcomes:
measure: hypopharyngeal mean peak pressure
timeFrame: 15 minutes
Secondary outcomes:
Other outcomes:
Locations:
city: Taipei
country: Taiwan
facility: Chih-Min Liu
Study officials:
References:
Clinical trial NCT05675228: Knowledge of Young Adults About Genital Herpes
Official title: Knowledge of Young Adults About Genital Herpes
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Genital Herpes
Keywords: Knowledge
Young adults
genital herpes
Lead sponsor: Université de Reims Champagne-Ardenne
Sponsor class: OTHER
First posted: 2023-01-09
Enrollment: 2000
Sex: ALL
Minimum age (years): 25
Maximum age (years): 35
Standard ages: ADULT
Accepts healthy volunteers: yes
Observational model: CASE_ONLY
Time perspective: CROSS_SECTIONAL
Sampling method: NON_PROBABILITY_SAMPLE
Study population: men and women aged 25 to 35, having sex or not and agreeing to participate in the study.

Brief summary: Despite sex education in schools and prevention campaigns concerning sexually transmitted infections, genital herpes remains frequent infection. In 2016, according to the World Health Organization, more than 490 million people worldwide were living with a genital herpes infection.

Detailed description: the aim of the study is to describe knowledge of adults aged 25 to 35 about genital herpes (symptoms, transmission, prevention).

Eligibility criteria: Inclusion Criteria:

* Men and women
* Aged 25 to 35
* Having sex or not
* Agreeing to participate in the study

Exclusion Criteria:

- Not agreeing to participate in this study

Primary outcomes:
measure: transmission
timeFrame: Day 0
measure: symptoms
timeFrame: Day 0
Secondary outcomes:
Other outcomes:
Locations:
city: Reims
country: France
facility: Fanny Bichon
Study officials:
References:
Clinical trial NCT01844128: The Effect of Weight Loss on Ovarian Reserve
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Weight Loss
Keywords: MMA, AFC, Ovarian reserve
Lead sponsor: Meir Medical Center
Sponsor class: OTHER
First posted: 2013-05-01
Enrollment: 100
Sex: FEMALE
Minimum age (years): 18
Maximum age (years): 43
Standard ages: ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Overweight women with infertility

Brief summary: Obesity affects on fertility. Obese women have lower pregnancy rate after infertility treatments.They need more doses of hormone during ovarian stimulation, more days for stimulation. During IVF treatment less oocytes are collected and the quality of embryo also harmed.

The first line treatment for those women with obesity and infertility is weight loss.

The investigators' hypothesis is that weight reduction improves ovarian reserve and fertility treatment outcome.

Detailed description: The investigators have outpatient clinic for obesity and infertility. the patients undergoing program of 3 months with diet and physical activity. Blood sample will take at the beginning of the program and at the end. The blood sample will evaluate for: AMH, Adiponectin, Leptin, CRP, Colesterol, CRP, Smac in addition TVUS will perform to evaluate AFC.

Eligibility criteria: Inclusion Criteria:

* undergoing weight loss program

Exclusion Criteria:

* dropp out before comletion the weighy loss target

Primary outcomes:
measure: Anti Mullerain Hormone (AMH)and AFC before and after weight loss
timeFrame: 3 months
Secondary outcomes:
Other outcomes:
Locations:
city: Kfar Sava
country: Israel
facility: Meir Medical Center
Study officials:
References:
Clinical trial NCT05354128: Thrombolysis in STEMI Patients Compared With pPCI on Recanalization Time in the Context of the COVID-19 Outbreak.
Official title: Intravenous Thrombolysis Versus Primary PCI for Recanalization Time in Acute ST-segment Elevation Myocardial Infarction in the Context of the COVID-19 Outbreak: a Prospective, Multicenter, Nonrandomized Controlled Registry Study.
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: STEMI - ST Elevation Myocardial Infarction
Lead sponsor: Shanghai 10th People's Hospital
Sponsor class: OTHER
First posted: 2022-04-29
Enrollment: 120
Sex: ALL
Minimum age (years): 18
Maximum age (years): 85
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: SINGLE_GROUP
Intervention model description: non-randomized control
Primary purpose: TREATMENT

Brief summary: During the outbreak of COVID-19, for patients with acute ST-segment elevation myocardial infarction with unclear infection, the time of primary PCI is uncertain, and it is often expected to exceed 90 minutes or even 120 minutes. In indicated patients, intravenous thrombolysis has significantly improved the recanalization time of criminal vessels.

Detailed description: During the outbreak of COVID-19, for patients with acute ST-segment elevation myocardial infarction with unclear infection, the time of primary PCI is uncertain, and it is often expected to exceed 90 minutes or even 120 minutes. In indicated patients, intravenous thrombolysis has significantly improved the recanalization time of criminal vessels. The purpose of this study was to compare the time from first medical contact to patency and safety (specifically symptom improvement, ECG ST segment) between intravenous thrombolysis and concurrent patients with possible primary PCI in a prospective, multicenter, non-randomized controlled manner. Significant fall, angiographic examination showed criminal blood vessel TIMI blood flow grade 2-3)

Eligibility criteria: Inclusion Criteria:

* ECG confirms acute ST-segment elevation myocardial infarction；The estimated time from FMC to recanalization is more than 120 minutes；

Exclusion Criteria:

* Intracranial hemorrhage or stroke within the past 6 months; central nervous system injury, tumor or arteriovenous malformation; bleeding disease with known cause; suspected aortic dissection; non-compressible puncture surgery within 24 hours, etc.; 1 week of pregnancy or postpartum; uncontrolled hypertension; advanced liver disease; active peptic ulcer; prolonged or invasive CPR;

Primary outcomes:
measure: recanalization
timeFrame: within 24 hours
measure: recanalization time
timeFrame: within 2 hours
Secondary outcomes:
measure: Major bleeding event
timeFrame: 7 day
measure: Malignant arrhythmia
timeFrame: 12 hours
Other outcomes:
Locations:
city: Shanghai
country: China
facility: Shanghai Tenth People's Hospital
state: Shanghai
Study officials:
affiliation: Shanghai 10th People's Hospital
name: Yawei Xu, Doctor
role: STUDY_DIRECTOR
References:
Clinical trial NCT03318328: Evaluation of Food Insecurity in Adults and Children With Cystic Fibrosis
Official title: Evaluation of Food Insecurity in Adults and Children With Cystic Fibrosis
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Cystic Fibrosis
Lead sponsor: St. Luke's Health System, Boise, Idaho
Sponsor class: OTHER
First posted: 2017-10-23
Enrollment: 87
Sex: ALL
Maximum age (years): 80
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: CASE_ONLY
Time perspective: OTHER
Sampling method: NON_PROBABILITY_SAMPLE
Study population: adults and parents of children with cystic fibrosis

Brief summary: A survey of adults and parents of children with cystic fibrosis on food insecurity

Detailed description: A survey of adults and parents of children with cystic fibrosis to determine any correlation between food insecurity and BMI or food insecurity and FEV1, and to determine what level of food insecurity is present.

Eligibility criteria: Inclusion Criteria: have CF and are willing to complete a questionnaire during a routine clinic visit

-

Exclusion Criteria:

* NA

Primary outcomes:
measure: Evaluate food insecurity incidence in CF patients
timeFrame: one time questionnaire administered during a clinic visit
Secondary outcomes:
measure: Determine if food insecurity leads to worse lung function in CF patients
timeFrame: one time questionnaire administered during a clinic visit
measure: Determine if food insecurity leads to worse BMI in CF patients
timeFrame: one time questionnaire administered during a clinic visit.
Other outcomes:
Locations:
Study officials:
References:
Clinical trial NCT04457128: Real-time Behavioral Interventions
Official title: Just-in-Time Adaptive Intervention to Reduce Sedentary Behavior
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Cancer
Aging
Comorbidities and Coexisting Conditions
Keywords: physical activity
ecological momentary assessment
health-related quality of life
Just-in-time adaptive intervention
Lead sponsor: University of Alabama, Tuscaloosa
Sponsor class: OTHER
Collaborators: name: University of Alabama at Birmingham
First posted: 2020-07-07
Enrollment: 200
Sex: ALL
Minimum age (years): 50
Maximum age (years): 75
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: FACTORIAL
Intervention model description: Micro-randomized trial
Primary purpose: PREVENTION

Brief summary: The goal of this study is to adapt an evidence-based sedentary behavior reduction intervention for men and women living in Alabama and determine its feasibility, acceptance, and limited efficacy.

Detailed description: The goal of this study is to adapt an evidence-based sedentary behavior reduction intervention for men and women living in Alabama and determine its feasibility, acceptance, and limited efficacy. Community-based Participatory Research methods will be used to adapt an evidence-based curriculum. The adapted curriculum will be delivered via print-based materials and a mobile phone app developed by an external collaborator.

Eligibility criteria: Inclusion Criteria:

* • 50 to 75 years old at study enrollment;

  * Currently living in Alabama;
  * Community-dwelling (i.e., not living in an assisted living facility or nursing home);
  * Having access to the internet and a smart phone;
  * Able to perform light-intensity physical activity (i.e., walking);
  * English speaking;
  * Willing to consent to study procedure.

Exclusion Criteria:

* Reporting more than 60 minutes of purposeful physical activity per week;
* Have an unstable mental condition that prevention study activities. Determined by the Physician Health questionnaire.

Primary outcomes:
measure: Usage
timeFrame: 16 weeks
measure: The Usage, Satisfaction, Ease of use Questionnaire
timeFrame: 16 weeks
Secondary outcomes:
measure: Change in sedentary time
timeFrame: Week 0 and Week 16
measure: Change in light-intensity physical activity
timeFrame: Week 0 and Week 16
Other outcomes:
Locations:
Study officials:
affiliation: University of Alabama at Birmingham
name: Raheem Paxton, PhD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT01564628: Data Acquisition for Optimization of Coronary Artery Disease (CAD) Algorithm
Official title: Data Acquisition for Optimization of Coronary Artery Disease Algorithm
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Coronary Artery Disease
Keywords: CAD
Lead sponsor: Acarix
Sponsor class: INDUSTRY
First posted: 2012-03-28
Enrollment: 306
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: CASE_ONLY
Time perspective: CROSS_SECTIONAL
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Patients referred to examination for Coronary Artery Disease

Brief summary: The purpose of the study is to optimize an already existing algorithm for diagnosing atherosclerosis of the coronary arteries (CAD, Coronary Artery Disease).

Detailed description: Acoustic information from the heart is obtained from patients referred to examination for Coronary Artery Disease. The acoustic signals are evaluated as indicators for CAD.

Eligibility criteria: Inclusion Criteria:

* At least 18 years old
* Referred to diagnostically Ca-CT, CT scan and/or CAG examination due to suspicion of coronary artery disease
* Subjects condition must be stable and the subject must not be referred due to suspicion of acute coronary syndrome
* Subject is willing to adhere to the study procedure
* Has signed the informed consent form and authorization to registration and publication of health information

Exclusion Criteria:

* Has acute coronary syndrome or stroke
* Arterial fibrillation
* Known severe arrhythmia or resting heart rate above 85 bpm
* Known diastolic murmurs due to heart valve disease
* Has had a previous by-pass operation, open chest surgery, donor heart or mechanical heart
* Reduced ejection fraction \< 50%
* Inability to understand or adhere to instructions for acoustic Data-acquisition (i.e. subject not able to hold breath due to KOL or asthma)
* Inability to perform CT-angio and/or subsequent CAG
* In active treatment for any cancer
* In active treatment for immunosuppression after transplantation
* Established or pursuing pregnancy or breast feeding
* Has damaged skin on the spot where the patch is placed during the recordings.

Primary outcomes:
measure: The Area Under the Receiver Operating Characteristic Curve of the CAD-score to Separate CAD From Non-CAD Patients.
timeFrame: Heart sound recordings measured on testday (25 minutes study period)
Secondary outcomes:
Other outcomes:
Locations:
city: Aarhus N
country: Denmark
facility: University Hospital of Aarhus, Skejby
Study officials:
affiliation: University Hospital of Aarhus, Skejby
name: Morten Bøttcher, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT04609228: Cardiac Surgery Outcomes in Blood-transfusion Acceptors and no Acceptors
Official title: Cardiac Surgery Outcomes in Blood-transfusion Acceptors and no Acceptors: a Retrospective Cohort Study
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Thoracic Surgery
Blood Transfusion; Hemoglobinemia
Cardiac Disease
Lead sponsor: Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau
Sponsor class: OTHER
First posted: 2020-10-30
Enrollment: 1911
Sex: ALL
Minimum age (years): 18
Maximum age (years): 100
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: RETROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Patients undergoing heart surgery in our hospital from 2009 to June 2020. Patients were categorized in blood-transfusion non-acceptors (exposed cohort) and blood-transfusion acceptors (control cohort)

Brief summary: The primary objective of this study is to analyze mortality after cardiac surgery in blood-transfusion non-acceptors (BTNA), and the secondary one to perform an adjusted comparison with a blood-transfusion acceptors (BTA) matched cohort.


Eligibility criteria: Inclusion Criteria:

* Patients undergoing heart surgery in our hospital from 2009 to June 2020

Exclusion Criteria:

* Preoperative hemoglobin lower than 120g/L
* EuroSCORE-II higher than 20%
* Heart transplant
* Assist device implantation
* Surgery of acute myocardial infarction-derived complications
* Other emergent cardiac surgeries (acute aortic dissection, heart injuries).

Primary outcomes:
measure: Change on Hemoglobin values from preoperative to end-of-surgery levels
timeFrame: End-of-surgery
Secondary outcomes:
measure: Rate of operative mortality
timeFrame: At discharge or within the first 30 postoperative days
measure: Intraoperative fluid balance
timeFrame: End of surgery
measure: Hemoglobin at discharge
timeFrame: At discharge, an average of 10 days
measure: Rate of postoperative morbidity
timeFrame: At discharge, an average of 10 days
Other outcomes:
Locations:
city: Barcelona
country: Spain
facility: Fundació de Gestió Sanitària de l'Hospital de la Santa Creu i Sant Pau
Study officials:
affiliation: Cardiac surgeon
name: Elena Roselló-Díez, MD, PhD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT02044328: Icotinib as an Adjuvant Therapy for Patients With Stage IIA-IIIA Adenocarcinoma With EGFR Mutation
Official title: Icotinib as an Adjuvant Therapy for Patients With Stage IIA-IIIA Adenocarcinoma With EGFR Mutation: a Prospective, Exploratory Study
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE2
Conditions: Non-small Cell Lung Cancer
Lead sponsor: Betta Pharmaceuticals Co., Ltd.
Sponsor class: INDUSTRY
First posted: 2014-01-23
Enrollment: 79
Sex: ALL
Minimum age (years): 18
Maximum age (years): 75
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: Adjuvant therapy has been proved effective in treating earlier stage or less advanced non-small-cell lung cancer. This study is designed to evaluate the efficacy of icotinib as adjuvant therapy in treating stage IIA-IIIA adenocarcinoma patients with EGFR mutation. The primary endpoint is disease-free survival.


Eligibility criteria: Inclusion Criteria:

* The patients present with operable stage IIA-IIIA (N0-1) lung adenocarcinoma with 19 or 21 exon mutation
* The patients have no history of anti-cancer therapies including chemotherapy, radiation therapy
* The patients' Eastern Cooperative Oncology Group scores are ≤ 0-1
* The patients signed the written informed consent

Exclusion Criteria:

* Patients with unresected tumor
* Wild EGFR type
* Allergic to the study drug
* Patients have severe non-cancerous diseases
* Patients are undergoing current administration of anti-cancer therapies, or are attending some other clinical trials

Primary outcomes:
measure: Disease-free survival
timeFrame: 2 years
Secondary outcomes:
measure: 1-year Survival Rates
timeFrame: 1 year
measure: 3-year Survival Rates
timeFrame: 3 years
measure: Number of patients suffered adverse events
timeFrame: 42 months
Other outcomes:
measure: Difference of disease-free survival by status of Bcl-2 interacting mediator of cell death
timeFrame: 2 years
Locations:
city: Beijing
country: China
facility: Xuanwu Hospital, Capital Medical University
state: Beijing
Study officials:
affiliation: Xuanwu Hospital, Beijing
name: Zhang Yi, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT04091828: Assessment of Cognitive Functions in Bipolar Patients
Official title: Assessment of Cognitive Functions in Bipolar Disorder Patients
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Bipolar Disorder
Lead sponsor: Assiut University
Sponsor class: OTHER
First posted: 2019-09-17
Enrollment: 72
Sex: ALL
Minimum age (years): 18
Maximum age (years): 55
Standard ages: ADULT
Accepts healthy volunteers: yes
Observational model: CASE_CONTROL
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: stable people not irritable

Brief summary: Assessment of cognitive function in manic bipolar patient

Detailed description: Assessment of severity of mania and depression in bipolar patients then evaluate their cognitive function.

Eligibility criteria: Inclusion Criteria:

* Aged 18-55 years
* Of both sex
* Diagnosed as bipolar by DSM-5(patient)

Exclusion Criteria:

* Current medical and psychiatric comorbidities which may affect cognitive status.
* Substance abuse or dependence (except nicotine and caffeine)in last month.
* Somatic treatment with drugs known to affect cognitive status (cortisol, antihistamines, etc.)

Primary outcomes:
measure: Assessment of severity of mania in bbipolar patients
timeFrame: 2019-2022
measure: Assessment of severity of depression in bipoiar patients
timeFrame: 2019-2022
measure: Assessment of cognitive function in bipoiar patients
timeFrame: 2019-2022
Secondary outcomes:
measure: Correlation between cognitive state in bipolar patient and(onset age,illness duration and number of episodes).
timeFrame: 2019-2021
Other outcomes:
Locations:
Study officials:
References: